FMTX News and Press, Forma Therapeutics Holdings Inc. From 01/07/22

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers , today announced that it will present at the 40 th Annual J.P. Morgan Healthcare Conf...

First Phase 2 combination trial results presented in oral session at 2021 ASH Annual Meeting Olutasidenib with azacitidine well tolerated with a safety profile largely consistent with olutasidenib alone ​ Molecular characteristics of olutasidenib monotherapy res...

The following slide deck was published by Forma Therapeutics Holdings, Inc. in conjunction with this event. For further details see: Forma Therapeutics Holdings (FMTX) presents at ASH Annual Meeting - Slideshow

Updated etavopivat Phase 1 trial results presented in two 2021 ASH Annual Meeting Oral Sessions Etavopivat was well tolerated with a safety profile consistent with underlying sickle cell disease Clinical data in 15 patients dosed for up to 12 weeks showed sustained inc...

Lone Pine Capital’s 13F portfolio value decreased from $31.03B to $29.68B. The number of positions increased from 36 to 39. They increased Twitter, Workday, and KE Holdings while dropping Global Payments and Mastercard. The top three positions are Shopify, Snap, and DoorDas...

Forma SCD Trend Report: The State of Transition survey reveals 62% of patients found the transition experience “moderately or very challenging” and 73% of physicians state there are a lack of transition guidelines and protocols in their practice or institution fo...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of Ifeyinwa (Ify) Osunkwo, MD, MPH, to the executive leadership team as the company’s inaugural chief pat...

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune syste...

Forma Therapeutics Holdings, Inc. (FMTX) Q3 2021 Earnings Conference Call November 12, 2021 08:00 AM ET Company Participants Mario Corso - Senior Director of IR Frank Lee - President and CEO Pat Kelly - Chief Medical Officer Dave Cook - Chief Scientific Officer Todd Shegog - CFO Conference Ca...

Forma Therapeutics (NASDAQ:FMTX): Q3 GAAP EPS of -$0.91 beats by $0.05. Cash, cash equivalents and marketable securities were $531.8M as of Sept. 30, 2021 Press Release For further details see: Forma Therapeutics EPS beats by $0.05